רומוסוזומאב
הערות שוליים

1 2 3  FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture
1 2  Evenity (romosozumab) Prescribing Information
↑  Menopause & Osteoporosis
↑  STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL
1 2  David G. Winkler, May Kung Sutherland, James C. Geoghegan, Changpu Yu, Trenton Hayes, John E. Skonier, Diana Shpektor, Mechtild Jonas, Brian R. Kovacevich, Karen Staehling‐Hampton, Mark Appleby, Mary E. Brunkow, John A. Latham Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
↑  Romosozumab
↑  Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016; 375:1532-1543. https://pubmed.ncbi.nlm.nih.gov/27641143/
↑  Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017 Oct 12;377(15):1417-1427. https://pubmed.ncbi.nlm.nih.gov/28892457/
↑  Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. https://pubmed.ncbi.nlm.nih.gov/19671655/
↑  Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017; 390:1585-1594. https://pubmed.ncbi.nlm.nih.gov/28755782/.
↑  Geusens P, Feldman R, Oates M, Thomas T, Makras P, Jakob F, Langdahl B, Wang Z, Rojeski M, Libanati C. Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis. Bone. 2022 Jan; 154:116209. https://pubmed.ncbi.nlm.nih.gov/34547521/
↑  Kenneth G. Saag, Jeffrey Petersen, Maria Luisa Brandi, Andrew C. Karaplis, Mattias Lorentzon, Thierry Thomas, Judy Maddox, Michelle Fan, Paul D. Meisner, Andreas Grauer, Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis, New England Journal of Medicine 377, 2017-10-12, עמ' 1417–1427 doi: 10.1056/NEJMoa1708322
↑  Felicia Cosman, Daria B. Crittenden, Jonathan D. Adachi, Neil Binkley, Edward Czerwinski, Serge Ferrari, Lorenz C. Hofbauer, Edith Lau, E. Michael Lewiecki, Akimitsu Miyauchi, Cristiano A.F. Zerbini, Cassandra E. Milmont, Li Chen, Judy Maddox, Paul D. Meisner, Cesar Libanati, Andreas Grauer, Romosozumab Treatment in Postmenopausal Women with Osteoporosis, New England Journal of Medicine 375, 2016-10-20, עמ' 1532–1543 doi: 10.1056/NEJMoa1607948
↑  Joshua Stokar, Auryan Szalat, Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study, The Journal of Clinical Endocrinology and Metabolism, 2024-03-14, עמ' dgae173 doi: 10.1210/clinem/dgae173
↑  Cream of life science entrepreneurs’ first venture was selling doughnuts
↑  Celltech Group plc - Interim Report 2002
↑  UCB Set to Buy U.K. Biotech Firm
↑  עלון לצרכן
הבהרה: המידע בוויקיפדיה נועד להעשרה בלבד ואינו מהווה ייעוץ רפואי.